Opaleye Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Opaleye Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-185,000	Closed	-$4.89M	–	61
2019 Q1	$4.89M	Buy	+185,000	New	+$4.38M	1.35%	30
2016 Q4	–	Sell	-275,000	Closed	-$4.99M	–	52
2016 Q3	$4.99M	Buy	275,000 +75,000	+38%	+$1.47M	2.61%	11
2016 Q2	$3.29M	Buy	+200,000	New	+$3.24M	2.2%	15
2015 Q1	–	Sell	-220,000	Closed	-$2.84M	–	45
2014 Q4	$2.84M	Buy	+220,000	New	+$2.75M	1.43%	28

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Opaleye Management's HZNP Position: Q2 2019 in Review

Opaleye Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 185,000 shares — an estimated $4.89M sold.

Opaleye Management first reported a position in HZNP in Q4 2014 and held it in 4 quarters. The position peaked at $4.99M in Q3 2016. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

Opaleye Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
Opaleye Management sold 185,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $4.89M.
Opaleye Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 4 quarters.
Opaleye Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.99M in Q3 2016.
272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.